Treatment

Displaying 11 - 20 of 202

Tech to drive next-gen therapies for MS

Tech to drive next-gen therapies for MS
Researchers in the University of Maryland (UMD) Fischell Department of Bioengineering (BIOE) Jewell Laboratory are using quantum dots to decipher the features needed to design specific and effective therapies for multiple sclerosis (MS) and other autoimmune diseases. Their findings were published as the cover story of Advanced Functional Materials.
14th June 2017

Ultrasound 'drill' targets deep vein blood clots

Ultrasound 'drill' targets deep vein blood clots
Researchers at North Carolina State University and the University of North Carolina at Chapel Hill have developed a new surgical tool that uses low-frequency intravascular ultrasound to break down blood clots that cause deep vein thrombosis. The tool is the first ultrasound 'drill' that can be aimed straight ahead, allowing doctors to better target clots—which holds promise for significantly reducing treatment time. To date, the technology has been tested only in synthetic blood vessels.
14th June 2017

Phagocytic protocells could targeted delivery of enzymes

Phagocytic protocells could targeted delivery of enzymes
Researchers at the University of Bristol have designed a community of artificial cell-like droplets that collectively displays a simple form of phagocytosis behaviour. The work provides an approach to designing complex life-like properties in non-living materials. The chemists have made a major advance in the construction of synthetic communities of artificial cells capable of mimicking phagocytosis—a complex biological process seen in living cells that enables the ingestion of foreign material by certain cell types.
13th June 2017


Hernia Repair Device receives FDA Clearance

Hernia Repair Device receives FDA Clearance
W. L. Gore & Associates has received U.S. FDA 510(k) clearance for its GORE SYNECOR Preperitoneal Biomaterial hernia repair device. The device is being launched at the Abdominal Wall Reconstruction (AWR) Conference in Washington, D.C. The Gore SYNECOR portfolio now offers treatment options for the full range of hernia cases, with configurations for both intraperitoneal and preperitoneal placement.
13th June 2017

World's first hybrid closed loop system treats Type 1 diabetes

World's first hybrid closed loop system treats Type 1 diabetes
Medtronic has announced the U.S. launch of the MiniMed 670G system - the world's first Hybrid Closed Loop system for people with type 1 diabetes. Featuring the company's most advanced SmartGuard HCL technology and Guardian Sensor 3, it is the only insulin pump approved by the FDA that enables personalised and automated delivery of basal insulin, the background insulin needed to maintain stable blood sugar levels throughout the day and night.
12th June 2017

Magnets and nanoparticles open and close gaps in blood vessels

Magnets and nanoparticles open and close gaps in blood vessels
The endothelial cells that line blood vessels are packed tightly to keep blood inside and flowing, but scientists at Rice University and their colleagues have discovered it may be possible to selectively open gaps in those barriers just enough to let large molecules through — and then close them again. Rice bioengineer Gang Bao and collaborators at Emory University and the Georgia Institute of Technology reported using magnets to help iron-oxide nanoparticles invade endothelial cells both in the lab and in vivo.
12th June 2017

Leukemia treatment outperforms standard chemotherapies

Leukemia treatment outperforms standard chemotherapies
Researchers at ANU are working on a new treatment for an aggressive type of leukemia that outperforms standard chemotherapies. Lead researcher Dr Nadine Hein from The John Curtin School of Medical Research at ANU said researchers have successfully treated highly aggressive acute myeloid leukemia (AML) in mice using the new treatment.
8th June 2017

Edwards SAPIEN 3 Valve receives FDA approval

Edwards SAPIEN 3 Valve receives FDA approval
Edwards Lifesciences Corporation has announced it has received U.S. FDA approval for aortic and mitral valve-in-valve procedures using the Edwards SAPIEN 3 transcatheter heart valve. The SAPIEN 3 valve is the first transcatheter heart valve approved in the U.S. for the treatment of both aortic and mitral patients who are at high risk for a subsequent open-heart surgery to replace their bioprosthetic valve.
7th June 2017

DABRA begins first commercial in-patient use

DABRA begins first commercial in-patient use
Ra Medical Systems has announced the commercial launch in the United States of the Company’s groundbreaking DABRA System for the treatment of Peripheral Artery Disease. This follows FDA clearance. Dr. Athar Ansari of the California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient today, performing the first ever DABRA case on arterial blockages via brachial artery access.
7th June 2017

Gene therapy could ‘switch off’ severe allergies

Gene therapy could ‘switch off’ severe allergies
A single treatment giving life-long protection from severe allergies such as asthma could be made possible by immunology research at The University of Queensland. A team led by Associate Professor Ray Steptoe at the UQ Diamantina Institute has been able to ‘turn-off’ the immune response which causes allergic reaction in animals. “When someone has an allergy or asthma flare-up, the symptoms they experience results from immune cells reacting to protein in the allergen,” Professor Steptoe said.
6th June 2017


Treatment documents


Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

EPE 2017 ECCE Europe
11th September 2017
Poland Warsaw
DSEI 2017
12th September 2017
United Kingdom ExCeL, London
RWM 2017
12th September 2017
United Kingdom NEC, Birmingham
Productronica India 2017
14th September 2017
India Pragati Maidan, New Delhi
Industry of Things World 2017
18th September 2017
Germany Berlin Congress Center